Skip to main content
Home > Week in Review > Management

Chronological Index of : Management Tracks

 Current Issue
  • BBB Therapeutics management update

    BBB Therapeutics B.V., Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Ferdinand Massari as CMO, formerly SVP and CMO of ImmusanT Inc. Transitioned: Pericles Calias to CSO from SVP of …

    Published on 10/6/2014
  • Biodesix management update

    Biodesix Inc., Bloomfield, Colo. Business: Diagnostic Hired: Richard Hockett as CMO, formerly CMO of CombiMatrix Corp.

    Published on 10/6/2014
  • Biota Pharmaceuticals management update

    Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Alpharetta, Ga. Business: Infectious, Neurology, Cancer Transitioned: Joseph Patti to president, CEO and a director from EVP of corporate development and strategy; he succeeds …

    Published on 10/6/2014
  • CereSpir board of directors update

    CereSpir Inc., New York, N.Y. Business: Neurology Appointed: Adrian Hobden as chairman

    Published on 10/6/2014
  • Cypher Genomics management update

    Cypher Genomics Inc., San Diego, Calif. Business: Genomics, Supply/Service Hired: J. Patrick Ravenel as chief technology officer, formerly VP of software development at Medimpact Healthcare Systems Inc.

    Published on 10/6/2014
  • Daiichi Sankyo management update

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Pharmaceuticals Transitioned: Koichi Akahane to head of R&D division, while remaining VP of R&D planning; Akahane succeeds Glenn Gormley

    Published on 10/6/2014
  • E3X Bio management update

    E3X Bio Inc., Menlo Park, Calif. Business: Cancer E3X Bio is headquartered in Menlo Park and is focused on cancer. The Sept. 22 BioCentury Week in Review misstated the location of company's headquarters and the company'…

    Published on 10/6/2014
  • Juno Therapeutics board of directors update

    Juno Therapeutics Inc., Seattle, Wash. Business: Cancer Appointed: Hal Barron, president of R&D at Calico LLC

    Published on 10/6/2014
  • Karolinska Development management update

    Karolinska Development AB (SSE:KDEV), Solna, Sweeden Business: Cancer, Infectious, Genitourinary Departed: Torbjorn Bjerke as CEO Transitioned: Klaus Wilgenbus to acting CEO from a director

    Published on 10/6/2014
  • Kymab board of directors update

    Kymab Ltd., Cambridge, U.K. Business: Antibodies Appointed: Lisha Patel, head of direct private investments at the Wellcome Trust

    Published on 10/6/2014
  • Kymab management update

    Kymab Ltd., Cambridge, U.K. Business: Antibodies Promoted: Jasper Clube to SVP of intellectual property and chief patent counsel; and Glenn Friedrich to COO from SVP of technology and research operations

    Published on 10/6/2014
  • Nanovi board of directors update

    Nanovi Radiotherapy A/S, Lyngby, Denmark Business: Cancer, Drug delivery Appointed: Flemming Thorup, president and CEO of 3Shape A/S, as chairman

    Published on 10/6/2014
  • NeoGenomics management update

    NeoGenomics Inc. (NASDAQ:NEO), Fort Myers, Fla. Business: Genomics, Diagnostic, Supply/Service Hired: Robert Shovlin as COO, effective Oct. 13, formerly chief development officer of Bostwick Laboratories Inc.

    Published on 10/6/2014
  • Nimbus Discovery management update

    Nimbus Discovery LLC, Cambridge, Mass. Business: Computational chemistry/biology, Endocrine/Metabolic, Inflammation Hired: Donald Nicholson as CEO, formerly VP and worldwide discovery head for the respiratory and …

    Published on 10/6/2014
  • Protalix management update

    Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX), Carmiel, Israel Business: Endocrine/Metabolic. Biosimilars, Biomanufacturing Hired: Moshe Manor as president and CEO, effective Nov. 2, formerly president at …

    Published on 10/6/2014
  • Retrophin management update

    Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Renal, Musculoskeletal, Pulmonary Departed: Martin Shkreli as CEO Transitioned: Stephen Aselage, a director, to interim CEO from president and COO

    Published on 10/6/2014
  • Ritter management update

    Ritter Pharmaceuticals Inc., Los Angeles, Calif. Business: Gastrointestinal Hired: Michael Step, a director, as CEO, formerly SVP of corporate development at Santarus Inc., which Salix Pharmaceuticals Ltd. acquired; he…

    Published on 10/6/2014
  • SQI Diagnostics board of directors update

    SQI Diagnostics Inc. (TSX-V:SQD; OTCQX:SQIDF), Toronto, Ontario Business: Diagnostic Appointed: Peter Winkley, a director, as chairman; he succeeds Claude Ricks, who remains a director

    Published on 10/6/2014
  • Takeda Pharmaceuticals Co. Ltd. management update

    Takeda Pharmaceuticals Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Pharmaceuticals Transitioned: Christophe Bianchi to president of Takeda's global oncology business unit from EVP of Takeda's Millennium …

    Published on 10/6/2014
  • Verona Pharma management update

    Verona Pharma plc (LSE:VRP), London, U.K. Business: Inflammation, Pulmonary Hired: Biresh Royas as CFO and a director; he succeeds Richard Bungay

    Published on 10/6/2014
  • Videregen board of directors update

    Videregen Ltd., Liverpool, U.K. Business: Transplant Appointed: Marc d'Abbadie, an investment director at SPARK Impact; and Robert Hollamby, an executive-in-residence at Symphony Technology Group

    Published on 10/6/2014
  • Visterra board of directors update

    Visterra Inc., Cambridge, Mass. Business: Infectious Appointed: Lincoln Chee, venture partner at Vertex Venture Holdings Ltd.

    Published on 10/6/2014
  • Vivione management update

    Vivione Biosciences Inc. (TSX-V:VBI), Pine Bluff, Ark. Business: Diagnostic Departing: Ted Moskal as president and president of Vivione's Vivion Biosciences LLC subsidiary Correction

    Published on 10/6/2014
  • Adaptimmune board of directors update

    Adaptimmune Ltd., Abingdon, U.K. Business: Cancer, Infectious, Gene/Cell therapy Appointed: Ali Behbahani, partner at New Enterprise Associates; David Mott, general partner at NEA; and Peter Thompson, private equity …

    Published on 9/29/2014
  • AmpliPhi BioSciences management update

    AmpliPhi Biosciences Corp. (OTCBB:APHB), Richmond, Va. Business: Infectious, Autoimmune, Gene/Cell therapy Resigned: Phillip Young as president and CEO, while remaining a director; Jeremy Cook, chairman, becomes interim…

    Published on 9/29/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993